Bioactivation of organic nitrates and the mechanism of nitrate tolerance

Cardiology Journal

Volumn 16, Issue 1, 2009, Pages 11-19

  Klemenska, Emila ^a   Beresewicz, Andrzej ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Endothelial dysfunction; Hydralazine; Nitrate tolerance; Organic nitrates; Oxidative stress

Indexed keywords

ALCOHOL; ALDEHYDE DEHYDROGENASE; ALPHA TOCOPHEROL; ANTIOXIDANT; APOCYNIN; ASCORBIC ACID; CARVEDILOL; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISULFIRAM; ENALAPRIL; FOLIC ACID; FREE RADICAL; GLYCEROL 1,2 DINITRATE; GLYCERYL TRINITRATE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANIC NITRATE; PLACEBO; PRAZOSIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; S NITROSOTHIOL;

ACUTE HEART INFARCTION; ADRENERGIC STIMULATION; ANGINA PECTORIS; ANTIOXIDANT ACTIVITY; AUTONOMIC DYSFUNCTION; BLURRED VISION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DRUG ALCOHOL INTERACTION; DRUG CROSS TOLERANCE; DRUG EFFICACY; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TOLERANCE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; EVIDENCE BASED PRACTICE; FLUSHING; HEART FAILURE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; REVIEW; SIDE EFFECT; STABLE ANGINA PECTORIS; TACHYPHYLAXIS; VASODILATATION;

ALDEHYDE DEHYDROGENASE; BIOTRANSFORMATION; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; ENDOTHELIUM, VASCULAR; ETHANOL; HUMANS; HYDRALAZINE; MITOCHONDRIA; NITRATES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SYMPATHETIC NERVOUS SYSTEM; TACHYPHYLAXIS; VASODILATION; VASODILATOR AGENTS;

EID: 60849099631     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Thadani U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther, 1997; 10: 735-742.
2. Abrams J, Elkayam U, Thadani U, Fung HL. Tolerance: An historical overview. Am J Cardiol, 1998; 81: A3-A14.
3. Fung HL. Biochemical mechanism of nitroglycerin action and tolerance: Is this old mystery solved? Annu Rev Pharmacol Toxicol, 2004; 44: 67-85.
4. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res, 2005; 97: 618-628.
5. Gori T, Floras JS, Parker JD. Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans. J Am Coll Cardiol, 2002; 40: 2000-2005.
6. Gori T, Parker JD. The puzzle of nitrate tolerance: Pieces smaller than we thought? Circulation, 2002; 106: 2404-2408.
7. Gori T, Parker JD. Nitrate-induced toxicity and preconditioning: A rationale for reconsidering the use of these drugs. J Am Coll Cardiol, 2008; 52: 251-254.
8. Daiber A, Mulsch A, Hink U et al. The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine. Am J Cardiol, 2005; 96: 25I-36I.
9. Mayer B, Beretta M. The enigma of nitroglycerin bioactivation and nitrate tolerance: News, views and troubles. Br J Pharmacol, 2008; 155: 170-184.
10. Daiber A, Wenzel P, Oelze M, Munzel T. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol, 2008; 97: 12-20.
11. Cheng JW. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clin Ther, 2006; 28: 666-678.
12. Carmody MS, Anderson JR. BiDil (isosorbide dinitrate and hydralazine): A new fixed-dose combination of two older medications for the treatment of heart failure in black patients. Cardiol Rev, 2007; 15: 46-53.
13. Cohn JN, Tam SW, Anand IS, Taylor AL, Sabolinski ML, Worcel M. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail, 2007; 13: 331-339.
14. Abrams J. The role of nitrates in coronary heart disease. Arch Intern Med, 1995; 155: 357-364.
15. Bauer JA, Booth BP, Fung HL. Nitric oxide donors: Biochemical pharmacology and therapeutics. Adv Pharmacol, 1995; 14: 361-381.
16. Bode-Boger SM, Kojda G. Organic nitrates in cardiovascular disease. Cell Mol Biol (Noisy-le-grand), 2005; 51: 307-320.
17. Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. Physiol Rev, 2008; 88: 1009-1086.
18. Munzel T, Feil R, Mulsch A, Lohmann SM, Hofmann F, Walter U. Physiology and pathophysiology of vascular signaling controlled by guanosine 3′, 5′-cyclic monophosphate-dependent protein kinase [corrected]. Circulation, 2003; 108: 2172-2183.
19. Chen Z, Stamler JS. Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med, 2006; 16: 259-265.
20. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA, 2002; 99: 8306-8311.
21. Chen Z, Foster MW, Zhang J et al. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci USA, 2005; 102: 12159-12164.
22. Daiber A, Oelze M, Coldewey M et al. Oxidative stress and mitochondrial aldehyde dehydrogenase activity: A comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol, 2004; 66: 1372-1382.
23. Mukerjee N, Pietruszko R. Inactivation of human aldehyde dehydrogenase by isosorbide dinitrate. J Biol Chem, 1994; 269: 21664-21669.
24. Crabb DW, Edenberg HJ, Bosron WF, Li TK. Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2(2) allele is dominant. J Clin Invest, 1989; 83: 314-316.
25. Larson HN, Zhou J, Chen Z, Stamler JS, Weiner H, Hurley TD. Structural and functional consequences of coenzyme binding to the inactive Asian variant of mitochondrial aldehyde dehydrogenase: roles of residues 475 and 487. J Biol Chem, 2007; 282: 12940-12950.
26. Li Y, Zhang D, Jin W et al. Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J Clin Invest, 2006; 116: 506-511.
27. Mackenzie IS, Maki-Petaja KM, Mceniery CM et al. Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler Thromb Vasc Biol, 2005; 25: 1891-1895.
28. Jugdutt BI, Warnica JW. Tolerance with low dose intravenous nitroglycerin therapy in acute myocardial infarction. Am J Cardiol, 1989; 64: 581-587.
29. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation, 1987; 76: 577-584.
30. Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol, 2005; 46: 63-67.
31. Thomas GR, DiFabio JM, Gori T, Parker JD. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: Evidence of a free-radical-mediated mechanism. J Am Coll Cardiol, 2007; 49: 1289-1295.
32. Mullenheim J, Muller S, Laber U et al. The effect of high-dose pentaerythritol tetranitrate on the development of nitrate tolerance in rabbits. Naunyn-Schmied Arch Pharmacol, 2001; 364: 269-275.
33. Gori T, Al Hesayen A, Jolliffe C, Parker JD. Comparison of the effects of pentaerythritol tetranitrate and nitroglycerin on endothelium-dependent vasorelaxation in male volunteers. Am J Cardiol, 2003; 91: 1392-1394.
34. Jurt U, Gori T, Ravandi A, Babaei S, Zeman P, Parker JD. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: A human in vivo study. J Am Coll Cardiol, 2001; 38: 854-859.
35. Hacker A, Muller S, Meyer W, Kojda G. The nitric oxide donor pentaerythritol tetranitrate can preserve endothelial function in established atherosclerosis. Br J Pharmacol, 2001; 132: 1707-1714.
36. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest, 1995; 95: 187-194.
37. Sydow K, Daiber A, Oelze M et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest, 2004; 113: 482-489.
38. Esplugues JV, Rocha M, Nunez C et al. Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrial-targeted antioxidants. Circ Res, 2006; 99: 1067-1075.
39. Wenzel P, Mollnau H, Oelze M et al. First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. Antioxid Redox Signal, 2008; 10: 1435-1447.
40. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly. Am J Physiol, 1996; 40: C1424-C1437.
41. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res, 2000; 87: 840-844.
42. Feletou M, Vanhoutte PM. Endothelial dysfunction: A multifaceted disorder. Am J Physiol, 2006; 291: H985-H1002.
43. Caramori PR, Adelman AG, Azevedo ER, Newton GE, Parker AB, Parker JD. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol, 1998; 32: 1969-1974.
44. Azevedo ER, Schofield AM, Kelly S, Parker JD. Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol, 2001; 37: 505-509.
45. Gori T, Mak SS, Kelly S, Parker JD. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol, 2001; 38: 1096-1101.
46. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation, 2000; 101: 948-954.
47. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 2000; 101: 1899-1906.
48. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation, 2001; 104: 2673-2678.
49. Katz SD, Hryniewicz K, Hriljac I et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation, 2005; 111: 310-314.
50. Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C. Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J, 1999; 138: 577-585.
51. Munzel T, Heitzer T, Kurz S et al. Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol, 1996; 27: 297-303.
52. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med, 1987; 317: 799-804.
53. Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation, 1991; 84: 2336-2345.
54. La Rovere MT, Pinna GD, Hohnloser SH et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: Implications for clinical trials. Circulation, 2001; 103: 2072-2077.
55. Lippincott's Illustrated Reviews: Pharmacology. 2 Ed. Lipincott, Williams & Wilkins, Philadelphia 2000.
56. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med, 1986; 314: 1547-1552.
57. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med, 1991; 325: 303-310.
58. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med, 2004; 351: 2049-2057.
59. Taylor AL, Ziesche S, Yancy CW et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: Consistency across subgroups in the African-American Heart Failure Trial. Circulation, 2007; 115: 1747-1753.
60. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation, 1991; 84: 35-39.
61. Unger P, Berkenboom G, Fontaine J. Interaction between hydralazine and nitrovasodilators in vascular smooth muscle. J Cardiovasc Pharmacol, 1993; 21: 478-483.
62. Munzel T, Kurz S, Rajagopalan S et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest, 1996; 98: 1465-1470.
63. Gogia H, Mehra A, Parikh S et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol, 1995; 26: 1575-1580.
64. Daiber A, Oelze M, Coldewey M et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun, 2005; 338: 1865-1874.
65. Elkayam U, Bitar F. Effects of nitrates and hydralazine in heart failure: Clinical evidence before the African-American heart failure trial. Am J Cardiol, 2005; 96: 37i-43i.